Where regulatory meets e-regulatory: bringing answers to the pharmaceutical industry.

Brazil & LATAM Pharmaceutical Regulations: Global Harmonisation & the Impact of Covid-19

Share this article

As global harmonisation becomes increasingly at the forefront of industry's focus, how are Brazil and the LATAM region looking to further advance towards a globally harmonised regulatory landscape?

We spoke to two industry experts, who will also be presenting at the Global Pharmaceutical Regulatory Affairs Summit, to find out their insight.  In addition, we explored the impact of COVID-19 and what bodies like ANVISA are doing to combat the pandemic.

Watch the video below to learn from:

  • Dr. Patrícia Kott Tomazett, Health Regulation Specialist, General Management of Drugs - GGMED at Brazilian Health Surveillance Agency (ANVISA), Brazil
  • Dr. Darius-Jean Namdjou, Global Regulatory Strategist at Grünenthal GmbH, Germany

Rebecca Brady, Senior Conference Producer at Informa Connect Life Sciences, led the discussion. Watch it now to hear their leading perspectives on the Brazil & LATAM regulatory landscape.

Share this article